Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - furosemide, quantity: 50 mg - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide; sodium chloride - oedema: furosemide-baxter injection is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. furosemide-baxter injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by the intravenous route. parenteral use should be replaced with oral frusemide as soon as practical.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - furosemide, quantity: 20 mg - injection, solution - excipient ingredients: sodium hydroxide; water for injections; sodium chloride; hydrochloric acid - oedema: furosemide-baxter injection is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. furosemide-baxter injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by the intravenous route. parenteral use should be replaced with oral frusemide as soon as practical.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium chloride, quantity: 1.1 g; glucose, quantity: 50 g - injection, solution - excipient ingredients: water for injections - sodium chloride (%) and glucose (%) intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium and chloride ion concentrations, it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - tranexamic acid, quantity: 100 mg/ml - injection - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - adults for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty. paediatrics for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - tranexamic acid, quantity: 100 mg/ml - injection - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - adults for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty. paediatrics for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - fluconazole, quantity: 200 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - fluconazole injection is indicated for the following conditions but should be used only when fluconazole cannot be administered orally: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (aids). 3. treatment of oropharyngeal and oesophageal candidiasis in patients with aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. 5. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice.

Australia - English - Department of Health (Therapeutic Goods Administration)

global harvest pharmaceuticals pty ltd - metaraminol tartrate, quantity: 9.5 mg (equivalent: metaraminol, qty 5 mg) - injection, solution - excipient ingredients: sodium metabisulfite; sodium chloride; water for injections - prevention and treatment of the acute hypotensive state occurring with spinal anaesthesia; adjunctive treatment of hypotension due to haemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to tumour or trauma. it may also be useful as an adjunct in the treatment of hypotension due to cardiogenic shock or septicaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

global harvest pharmaceuticals pty ltd - metaraminol tartrate, quantity: 5.7 mg (equivalent: metaraminol, qty 3 mg) - injection, solution - excipient ingredients: sodium metabisulfite; sodium chloride; water for injections - prevention and treatment of the acute hypotensive state occurring with spinal anaesthesia; adjunctive treatment of hypotension due to haemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to tumour or trauma. it may also be useful as an adjunct in the treatment of hypotension due to cardiogenic shock or septicaemia

Australia - English - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - sodium valproate, quantity: 1000 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - valwok is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Australia - English - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - sodium valproate, quantity: 400 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - valwok is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.